Kurt Rasmussen

Eli Lilly, Indianapolis, IN, United States 
"Kurt Rasmussen"
Mean distance: 14.85 (cluster 19)


Sign in to add trainee
Matthew A. Seager post-doc 2002-2005
Gavin Stewart Dawe research scientist 2000-2001 Eli Lilly
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Marek GJ, Cunningham KA, Rasmussen K. (2019) Translating Pharmacology into Therapeutics to Fight the Opioid Crisis. The Journal of Pharmacology and Experimental Therapeutics. 371: 394-395
Balcer OM, Seager MA, Gleason SD, et al. (2018) Evaluation of 5-HT receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research. 360: 270-278
Witkin JM, Mitchell S, Wafford K, et al. (2017) Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist, in Rodents: Evidence Supporting Use for the Treatment of Depression. The Journal of Pharmacology and Experimental Therapeutics
Kato AS, Burris KD, Gardinier KM, et al. (2016) Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism. Nature Medicine
Witkin JM, Monn JA, Schoepp DD, et al. (2016) The Rapidly-Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. The Journal of Pharmacology and Experimental Therapeutics
Fell MJ, Katner JS, Rasmussen K, et al. (2012) Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade. Frontiers in Psychiatry. 3: 49
Fell MJ, Witkin JM, Falcone JF, et al. (2011) N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. The Journal of Pharmacology and Experimental Therapeutics. 336: 165-77
Gehlert DR, Rasmussen K, Shaw J, et al. (2009) Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. The Journal of Pharmacology and Experimental Therapeutics. 329: 429-38
Rasmussen K, Hsu MA, Noone S, et al. (2007) The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. Schizophrenia Bulletin. 33: 1291-7
Rasmussen K, Hsu MA, Yang Y. (2007) The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 786-92
See more...